Shares in Oldwick, N.J.-based Provention Bio began trading today following the close of its $64 million initial public offering last week.
The biopharmaceutical company, lead by co-founder & CEO Ashleigh Palmer, is developing a number of products that aim to prevent or stop the spread of immune-mediated diseases, including Lupus, Crohn’s disease and Type I diabetes.
Provention Bio’s strategy is to find drugs that have been developed by other pharmaceutical companies and take them through the clinical development process. But Palmer draws a clear distinction – the company is not “sifting through the trashcan of big pharma.”
Get the full story at our sister site, Drug Delivery Business News.